alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 45 (Tuesday, March 9, 2010)]
[Notices]
[Page 10822]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4904]


-----------------------------------------------------------------------

DEPARTMENT OF LABOR

Employment and Training Administration

[TA-W-73,157]


FCI USA, LLC Including On-Site Leased Workers From Manpower, 
Inc.; Mount Union, PA; Amended Certification Regarding Eligibility To 
Apply for Worker Adjustment Assistance

    In accordance with Section 223 of the Trade Act of 1974, as amended 
(``Act''), 19 U.S.C. 2273, the Department of Labor issued a 
Certification of Eligibility to Apply for Worker Adjustment Assistance 
on January 22, 2010, applicable to workers of FCI USA, LLC, including 
on-site leased workers from Manpower, Inc., Mount Union, Pennsylvania. 
The notice will be published soon in the Federal Register.
    At the request of the State Agency, the Department reviewed the 
certification for workers of the subject firm. The workers are engaged 
in activities related to the production of electrical components for 
various communications devices, personal computers, and auto 
dashboards.
    The review shows that on February 21, 2008, a certification of 
eligibility to apply for adjustment assistance was issued for all 
workers of FCI USA, Inc., Mount Union, Pennsylvania, separated from 
employment on or after September 28, 2007 through February 21, 2010. 
The notice was published in the Federal Register on March 7, 2008 (73 
FR 12466).
    In order to avoid an overlap in worker group coverage, the 
Department is amending the December 22, 2008 impact date established 
for TA-W-73,157, to read February 22, 2010.
    The amended notice applicable to TA-W-73,157 is hereby issued as 
follows:

    All workers of FCI USA, LLC, including on-site leased workers 
from Manpower, Inc., Mount Union, Pennsylvania, who became totally 
or partially separated from employment on or after February 22, 
2010, through January 22, 2012, and all workers in the group 
threatened with total or partial separation from employment on date 
of certification through two years from the date of certification, 
are eligible to apply for adjustment assistance under Chapter 2 of 
Title II of the Trade Act of 1974, as amended.

    Signed in Washington, DC, this 3rd day of March 2010.
Elliott S. Kushner,
Certifying Officer, Division of Trade Adjustment Assistance.
[FR Doc. 2010-4904 Filed 3-8-10; 8:45 am]
BILLING CODE 4510-FN-P
(logo) pwc

 

 

**Report of IndependentRegistered Public Accounting Firm**

 

 

To the Board of Directors andshareholders of CoreLogic, Inc.:

 

We have examinedmanagement’s assertion, included in the accompanying Report on Assessmentof Compliance, that CoreLogic Commercial Real Estate Services, Inc. (the"Company"), a subsidiary of CoreLogic, Inc. complied with theservicing criteria set forth in Item 1122(d) of the Securities and ExchangeCommission's Regulation AB for all loans for commercial mortgage loanoutsourcing customers for which the Company served as the commercial tax serviceprovider (the "Platform"), as of December 31, 2016 and for the yearthen ended, only including 1122(d)(1)(iv), 1122(d)(2)(ii), 1122(d)(2)(v),1122(d)(2)(vi), 1122(d)(2)(vii), 1122(d)(4)(xi), 1122(d)(4)(xii) and1122(d)(4)(xiii), which the Company has determined are applicable to theservicing activities performed by it with respect to the Platform. Managementis responsible for the Company's compliance with the servicing criteria. Ourresponsibility is to express an opinion on management's assertion based on ourexamination.

 

Our examination was conductedin accordance with attestation standards of the Public Company AccountingOversight Board (United States) and, accordingly, included examining, on a testbasis, evidence about the Company’s compliance with the applicableservicing criteria and performing such other procedures as we considerednecessary in the circumstances. Our examination included testing of selectedservicing activities related to the Platform, and determining whether theCompany performed those selected activities in compliance with the applicableservicing criteria. Our procedures were limited to the selected servicingactivities performed by the Company during the period covered by this report.Our procedures were not designed to detect noncompliance arising from errorsthat may have occurred prior to or subsequent to our tests that may haveaffected the balances or amounts calculated or reported by the Company duringthe period covered by this report. We believe that our examination provides areasonable basis for our opinion. Our examination does not provide a legaldetermination on the Company’s compliance with the servicing criteria.

 

In our opinion,management’s assertion that the Company complied with the aforementioned applicableservicing criteria as of and for the year ended December 31, 2016 for all loansfor commercial mortgage loan outsourcing customers for which the Company servedas the commercial tax service provider is fairly stated, in all materialrespects.

 

/s/ PricewaterhouseCoopers

 

February 6, 2017

 

 

*PricewaterhouseCoopers LLP,2001 Ross Avenue, Suite 1800, Dallas TX 75201-2997*

*T: 214-746-6500, F:214-712-6660,*www.pwc.com
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3540 Prosthesis modification instrument for ossicular replacement surgery. ( a ) *Identification.* A prosthesis modification instrument for ossicular replacement surgery is a device intended for use by a surgeon to construct ossicular replacements. This generic type of device includes the ear, nose, and throat cutting block; wire crimper, wire bending die; wire closure forceps; piston cutting jib; gelfoamTM punch; wire cutting scissors; and ossicular finger vise.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 874.9. If the device is not labeled or otherwise represented as sterile, it is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180 of this chapter, with respect to general requirements concerning records, and § 820.198 of this chapter, with respect to complaint files.
[51 FR 40389, Nov. 9, 1986, as amended at 52 FR 32111, Aug. 25, 1987; 65 FR 2316, Jan. 14, 2000]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7040 Adenosine triphosphate release assay. ( a ) *Identification.* An adenosine triphosphate release assay is a device that measures the release of adenosine triphosphate (ATP) from platelets following aggregation. This measurement is made on platelet-rich plasma using a photometer and a luminescent firefly extract. Simultaneous measurements of platelet aggregation and ATP release are used to evaluate platelet function disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60609, Sept. 12, 1980, as amended at 84 FR 71799, Dec. 30, 2019]
Exhibit 32.1
 CERTIFICATION PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934
  (1)
    
    the Report fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934, as amended; and
 (2)
    
    the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
 May 14, 2009
    By:
    /s/ Michael BrodskyMichael BrodskyPresident and Chief Executive OfficerMay 14, 2009
    By:
    /s/ Michael NelsonMichael NelsonChief Accounting Officer
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4685 Extracorporeal shock wave device for treatment of chronic wounds. ( a ) *Identification.* An extracorporeal shock wave device for treatment of chronic wounds is a prescription device that focuses acoustic shock waves onto the dermal tissue. The shock waves are generated inside the device and transferred to the body using an acoustic interface.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Non-clinical performance testing must be conducted to demonstrate that the system produces anticipated and reproducible acoustic pressure shock waves.
( 2 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 3 ) Performance data must demonstrate that the reusable components of the device can be reprocessed for subsequent use.
( 4 ) Performance data must be provided to demonstrate the electromagnetic compatibility and electrical safety of the device.
( 5 ) Software verification, validation, and hazard analysis must be performed.
( 6 ) Performance data must support the use life of the system by demonstrating continued system functionality over the labeled use life.
( 7 ) Physician labeling must include: ( i ) Information on how the device operates and the typical course of treatment;
( ii ) A detailed summary of the device's technical parameters;
( iii ) Validated methods and instructions for reprocessing of any reusable components; and
( iv ) Instructions for preventing hearing loss by use of hearing protection.
( 8 ) Patient labeling must include: ( i ) Relevant contraindications, warnings, precautions, adverse effects, and complications;
( ii ) Information on how the device operates and the typical course of treatment;
( iii ) The probable risks and benefits associated with the use of the device;
( iv ) Post-procedure care instructions; and
( v ) Alternative treatments.
[83 FR 9699, Mar. 7, 2018]
Exhibit 10.3

[MBIA INC. LETTERHEAD]

Mitchell Sonkin

163 Lake Ave

Greenwich, CT 06830

Employment Agreement Extension

Dear Mitch:

We refer to your
letter agreement (the Employment Agreement), dated August 4, 2009, setting forth the terms pursuant to which you have continued to be an employee of MBIA Insurance Corporation or one of its affiliates (the
Employer), and an officer of MBIA Inc. (MBIA) and one or more of its subsidiaries through June 30, 2010, subject to such extension as may be mutually agreed by you, MBIA and the Employer. As
provided in Section 1 of the Employment Agreement, you, MBIA and the Employer hereby mutually agree to extend the Employment Period (within the meaning of the Employment Agreement) through June 30, 2011. Accordingly, the terms and
conditions set forth in the Employment Agreement shall continue until June 30, 2011, unless you, MBIA and the Employer shall mutually agree to further extend the Employment Period or enter into a new agreement.

For your convenience, a copy of the Employment Agreement is attached to this letter.

Please confirm your acceptance of the extension of the Employment Period as set forth above by signing below.

Sincerely,





|                                    
|------------------------------------
|                                    
|/s/ Joseph W. Brown                 
|Joseph W. Brown                     
|Chairman and Chief Executive Officer

|                     |  |                    
|-------------------- |  | -------------------
|                     | 
|Agreed and Accepted: |  | /s/ Mitchell Sonkin
|                     |  | Mitchell Sonkin    

Dated:
May 5, 2010



1
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3560 Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis. ( a ) *Identification.* A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).
( b ) *Classification.* Class II.
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.5880 Multi-function physical therapy table. ( a ) *Identification.* A multi-function physical therapy table is a device intended for medical purposes that consists of a motorized table equipped to provide patients with heat, traction, and muscle relaxation therapy.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5640 Lamb feeding nipple. ( a ) *Identification.* A lamb feeding nipple is a device intended for use as a feeding nipple for infants with oral or facial abnormalities.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 880.9. If the device is not labeled or otherwise represented as sterile, it is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[45 FR 69682, Oct. 21, 1980, as amended at 66 FR 38804, July 25, 2001]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.6400 Hematocrit measuring device. ( a ) *Identification.* A hematocrit measuring device is a system consisting of instruments, tubes, racks, and a sealer and a holder. The device is used to measure the packed red cell volume in blood to determine whether the patient's total red cell volume is normal or abnormal. Abnormal states include anemia (an abnormally low total red cell volume) and erythrocytosis (an abnormally high total red cell mass). The packed red cell volume is produced by centrifuging a given volume of blood.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 864.9.
[45 FR 60606, Sept. 12, 1980, as amended at 63 FR 59225, Nov. 3, 1998]
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Standards for Guiding Monetary Action

              																	United States. Congress. Joint Economic Committee, 1956-					 and 	Ninetieth Congress, 1967-1969. 						*Standards for Guiding Monetary Action : Report of the Joint Economic Committee, Congress of the United States*,												Washington: 								U.S. Government Printing Office, 										1968,									https://fraser.stlouisfed.org/title/795,			accessed on September 7, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, April 27, 2017. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, April 27, 2017 The Court of Appeals hereby passes the following order A17D0372. W.K. BISHOP v. LYNN MARIE HARRISON. Upon consideration of the Application for Discretionary Appeal, it is ordered that it be hereby DENIED.
LC NUMBERS: 2015CV258539